Reuters Analysis Finds Prices for Drugs First Entering the Market More Than
Doubled in Four Years





 



DOSE OF REALITY: BIG PHARMA SETS NEW RECORD FOR OUT-OF-CONTROL LAUNCH PRICES

Reuters Analysis Finds Prices for Drugs First Entering the Market More Than
Doubled in Four Years



In case you missed it, launch prices for prescription drugs first entering the
market in the United States more than doubled last year compared to 2021,
according to a new Reutersanalysis
<[link removed]>
. Big Pharma has been setting increasingly out-of-control launch prices on new
medications when they face no competition in the market and have the greatest
possible remaining periods of exclusivity — routinely extended through abuse of
the U.S. patent system.



“The increase in prices has occurred even as the U.S. government tries to rein
in prescription costs,” Reuters notes. “Drug pricing has become a populist
issue for President Donald Trump, who has called for drugmakers to bring U.S.
prices in line with other high-income nations that pay far less.”



Of the 45 medicines surveyed in 2024, the median annual list price was more
than $370,000 compared to a median launch price of $300,000 in 2023 and
$222,000 in 2022. A separatestudy
<[link removed]> published
in the JAMA Network, based on the same criteria as the Reuters survey, found
that the median launch price for 30 drugs was $180,000 in 2021. That study,
conducted by researchers affiliated with Harvard University and Brigham and
Women’s Hospital, found that for 14 years, “from 2008 to 2021, launch prices
for new drugs increased by 20 percent per year.”



“There is no indication that the trend will slow,” William Padula, professor
of pharmaceutical and health economics at the University of Southern
California, told Reuters.



Big Pharma’s egregious pricing practices, including setting out-of-control
launch prices on new products and anti-competitive tactics, impose an
unsustainable burden on American patients, taxpayers and the U.S. health care
system.



To hold Big Pharma accountable for outrageous launch prices, The Campaign for
Sustainable Rx Pricing (CSRxP) supports policies to require drug makers to
justify their prices, including through studies that can compare new drugs to
existing ones on the market. CSRxP also supports the U.S. Department of Health
and Human Services (HHS) issuing an annual report on launch prices and trends
to monitor their impact on consumers and taxpayers. Additionally, the
Patient-Centered Outcomes Research Institute (PCORI) and the Agency for
Healthcare Research and Quality (AHRQ) should be empowered with the resources
and authorities necessary to conduct cost-effectiveness work to assess whether
launch prices and ongoing price increases align with actual value to patients.



Read the Reuters article HERE
<[link removed]>
.



Read more on bipartisan, market-based solutions to hold Big Pharma accountable
HERE <[link removed]>.



###

































Copyright © 2019 Campaign for Sustainable Rx Pricing
Our address is 1341 G St NW, #1100, Washington, DC xxxxxx


This email was sent to [email protected]. To unsubscribe please click
here.
<[link removed]>